Document is current
Any future updates will be listed below
-
Authors
Ciciani, Matteo
Demozzi, Michele https://orcid.org/0000-0002-4577-3694
Pedrazzoli, Eleonora https://orcid.org/0000-0002-8420-2587
Visentin, Elisabetta https://orcid.org/0000-0001-6586-4123
Pezzè, Laura
Signorini, Lorenzo Federico https://orcid.org/0000-0002-9727-1987
Blanco-Miguez, Aitor https://orcid.org/0000-0001-7386-5572
Zolfo, Moreno https://orcid.org/0000-0001-6661-4046
Asnicar, Francesco https://orcid.org/0000-0003-3732-1468
Casini, Antonio
Cereseto, Anna https://orcid.org/0000-0003-4453-2597
Segata, Nicola https://orcid.org/0000-0002-1583-5794
-
Funding
Funding for this research was provided by:
EC | Horizon 2020 Framework Programme (825825)
- License Information
-
More Information
Article History
Received: 31 August 2022
Accepted: 17 October 2022
First Online: 29 October 2022
Competing interests
: The authors declare competing financial interests: A.Ce. is a co-founder and holds shares of Alia Therapeutics, a genome editing company. A.Ca. is a co-founder, holds shares and is currently an employee of Alia Therapeutics. L.P. is an employee of Alia Therapeutics. M.C. and N.S. are consultants of Alia Therapeutics. N.S., M.C., A.Ce., and A.Ca. are inventors of a US provisional patent application (no. 63/356,173) filed by Alia Therapeutics to cover the PAM prediction pipeline described in the present work. The remaining authors declare no competing interests.
